Aptamers are promising affinity reagents that are potentially well suited for high-throughput discovery, as they are chemically synthesized and discovered via completely in vitro selection processes. Recent advancements in selection, sequencing, and the use of modified bases have improved aptamer quality, but the overall process of aptamer generation remains laborious and low-throughput. This is because binding characterization remains a critical bottleneck, wherein the affinity and specificity of each candidate aptamer are measured individually in a serial manner. To accelerate aptamer discovery, we devised the Quantitative Parallel Aptamer Selection System (QPASS), which integrates microfluidic selection and nextgeneration sequencing with in situ-synthesized aptamer arrays, enabling simultaneous measurement of affinity and specificity for thousands of candidate aptamers in parallel. After using QPASS to select aptamers for the human cancer biomarker angiopoietin-2 (Ang2), we in situ synthesized arrays of the selected sequences and obtained equilibrium dissociation constants (K d ) for every aptamer in parallel. We thereby identified over a dozen high-affinity Ang2 aptamers, with K d as low as 20.5 ± 7.3 nM. The same arrays enabled us to quantify binding specificity for these aptamers in parallel by comparing relative binding of differentially labeled target and nontarget proteins, and by measuring their binding affinity directly in complex samples such as undiluted serum. Finally, we show that QPASS offers a compelling avenue for exploring structure−function relationships for large numbers of aptamers in parallel by coupling array-based affinity measurements with next-generation sequencing data to identify nucleotides and motifs within the aptamer that critically affect Ang2 binding.
S
ince the invention of hybridoma monoclonal antibodies (1) , affinity reagents that bind specifically to target molecules have become a cornerstone of modern biotechnology. The demand for high-quality affinity reagents has increased sharply as researchers continue to discover remarkable diversity within the proteome, with many closely related but functionally distinct protein variants arising through processes such as alternative splicing and posttranslational modification (2, 3) . Unfortunately, conventional methods of generating monoclonal antibodies (e.g., hybridoma production) are inherently low-throughput, and there is a pressing need for alternative technologies that can generate high-quality affinity reagents to meet this growing demand in a high-throughput and economical manner (4) . Toward this end, nucleic acid aptamers represent a compelling class of affinity reagents. Aptamers are chemically synthesized and their discovery is performed in vitro rather than relying on in vivo biological processes, making them potentially well suited for high-throughput discovery (5, 6) . Furthermore, aptamers with high affinity and specificity have been previously reported for a wide range of molecular targets including proteins (7, 8) , small molecules (9) , and cell surface markers (10, 11) , and chemically modified and nonnatural nucleic acids have introduced an expanded repertoire of functional groups and structural conformations that can further improve binding affinity and specificity (12) .
Recent advancements in selection and sequencing techniques have greatly increased the efficiency of aptamer discovery. For example, novel separation methodologies such as capillary electrophoresis (13, 14) and microfluidic devices (15) (16) (17) can isolate high-affinity aptamers after a minimal number of selection rounds. This increased efficiency is achieved through tighter control over selection stringency by applying rigorous washing to isolate aptamers with slow off-rates or by using minimal target quantities to establish a highly competitive binding environment. Furthermore, next-generation sequencing (NGS) has enabled analysis of far greater numbers of aptamer sequences than those obtained via standard bacterial cloning techniques. Traditional selection techniques depend on the convergence of the aptamer pool toward a relatively small number of sequences, such that consensus motifs can be obtained from a few hundred sequences. NGS can analyze millions of sequences, thus identifying enriched sequences much earlier in the selection process; this reduces the number of selection rounds required, and enables the identification and elimination of artifacts that typically arise over repeated rounds of PCR or during the cloning process (18) (19) (20) . Despite these advances, the generation of high-quality aptamers remains a time-consuming and low-throughput process. This is because aptamer binding is still characterized in a serial fashion, with the affinity and specificity of each candidate aptamer measured individually. Thus, to truly accelerate aptamer
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The authors declare no conflict of interest. discovery, it is necessary to alleviate this bottleneck by devising a strategy that enables binding characterization of large numbers of aptamers in a massively parallel manner.
As a solution to this problem, we describe an integrated aptamer discovery platform that enables simultaneous measurement of affinity and specificity for thousands of aptamers (Fig. 1) . Our Quantitative Parallel Aptamer Selection System (QPASS) integrates microfluidic aptamer selection (M-SELEX) and NGS to identify potential high-affinity aptamers, which are then synthesized in situ on an aptamer array for binding characterization. Previous studies have used aptamer arrays to explore the relationship between sequence and function for existing aptamers (21, 22) . Here we integrated selection and NGS to discover unique aptamers by measuring the binding affinity and specificity of a large numbers of aptamers in parallel. After performing four rounds of M-SELEX and NGS analysis with our model target, human angiopoietin-2 (Ang2), we used our aptamer arrays to simultaneously measure equilibrium dissociation constants (K d ) for ∼1,000 candidate aptamers in parallel, identifying six high-affinity Ang2 aptamers with K d < 30 nM. In addition, these aptamer arrays also allowed us to quantify the relative binding specificity of our aptamers for Ang2 relative to other, nontarget proteins via a two-color fluorescence measurement scheme. Finally, we used our arrays to generate binding data in undiluted serum, enabling us to specifically identify aptamers with optimal binding characteristics in complex, clinical samples.
Results
Aptamer Library Design and Microfluidic Selection. We chose Ang2 as a model target because it is an important mediator of angiogenesis and a biomarker of colon, prostate, and breast cancers (23, 24) . The monomeric Ang2 used in this experiment is 66 kDa in size, with an isoelectric point of 5.5 (25) . Previously, 2′ fluoromodified RNA aptamers for Ang2 have been reported by the Sullenger group (7), but no DNA aptamer has been reported. To begin the selection, we immobilized Ang2 onto carboxylic acidfunctionalized magnetic beads via ethyl(dimethylaminopropyl) carbodiimide (EDC)−NHS coupling reaction. To verify that the conformation of Ang2 was preserved on the magnetic beads, we confirmed that binding of monoclonal anti-Ang2 antibody was unaffected by immobilization (SI Appendix, Fig. S1 ). We minimized nonspecific binding of DNA to the bead surface by tuning the hydroxyl passivation layer, as previously described (15) .
Each member of our aptamer library consists of a 40-nt random core region flanked by two 20-nt primer-binding regions for PCR amplification (Methods). We performed four rounds of M-SELEX using the micromagnetic separation (MMS) device previously developed by our group (16) , which allowed us to uniformly control the selection and washing stringency (15) (16) (17) (18) . Although the MMS device is capable of performing highly stringent washing, we used moderate selection conditions for this experiment. This is because higher stringency selection generally results in convergence toward an aptamer pool in which a small number of candidate aptamer sequences predominate, whereas the goal of this experiment was to maintain greater sequence diversity to demonstrate massively parallel characterization of large numbers of aptamers (see Methods for a description of selection conditions). After each round (R) of selection, we PCR-amplified the enriched aptamers from each pool (R1−R4) and enzymatically digested the double-stranded amplicons to generate single-stranded DNAs for subsequent rounds of selection (16) . To monitor enrichment progress, we collected an aliquot from each pool to measure the bulk K d via a bead-based fluorescence assay (Methods). We found that the initial library, R1, R2, and R3 pools exhibited minimal binding, but observed a noticeable increase in the affinity of the R4 pool (SI Appendix, Fig. S2 ). As described in the literature, pools from early rounds of selection are dominated by nonspecific and low-affinity binders, and the average affinity of the pool subsequently increases in later rounds as these sequences are purged (26) . Accordingly, by R4, the high-affinity sequences were becoming prominently enriched, making it possible to begin identifying candidate aptamers suitable for further characterization.
Sequencing and Aptamer Array Design. To quantitatively identify aptamer sequences that were enriched in each round of M-SELEX, we sequenced the R1−R4 pools with the Illumina Genome Analyzer IIx (27) . Briefly, we PCR-amplified the pools at an optimum cycle number determined by pilot PCR, and then used the single-read Chip-Seq DNA Sample Prep Kit (Illumina) to prepare double-stranded products for sequencing. This yielded ∼3 × 10 7 sequences from each pool (SI Appendix, Table S1 ). For quality control purposes, we filtered out sequences of incorrect length or those containing mismatches of more than one base within the primer-binding regions. After filtering, we trimmed the primer-binding regions, leaving only the 40-nt core aptamer sequence for downstream analysis. Many different approaches have been described in the literature to discriminate high-affinity aptamers from undesired background sequences arising from selection biases. These methods include enrichment fold (18) , repeating motif (8) , and copy number (19, 20) analysis. We chose copy number analysis to test our capacity to directly distinguish high-affinity aptamers from background sequences via parallel binding measurements. We therefore rank-ordered all sequences from each pool (R1−R4) based on their copy number, and used this information to identify subsets of putative high-affinity aptamers for further characterization.
We devised an array-based strategy to simultaneously characterize the affinities and specificities of candidate aptamers in parallel. We fabricated a custom aptamer chip (Agilent Technologies; Methods) containing eight identical arrays of 15,000 features. Each array incorporated the 235 most highly represented aptamer candidates from each of the four selection rounds as well as 65 control sequences (SI Appendix, Table S2 ), with each sequence represented by three copies to enable triplicate measurement. Agilent arrays can accommodate sequences of up to 60 nt in length, but the aptamers we selected were 80 nt in length, including 20-nt forward and reverse primer-binding regions. We therefore excised the primer-binding regions, which further allowed us to effectively screen for aptamers that retain their function without those sequences. To provide relief from the array surface (21), we tested every aptamer with four different linker types in the array (SI Appendix, Table S3 ). We achieved best performance with the poly-T linker, and these are the results reported below. sequences that we subsequently analyzed for copy number and sequence homology. (Right) Based on these data, we generated a chip consisting of eight identical in situ-synthesized aptamer arrays containing ∼15,000 aptamers, in which each of the 235 top candidate aptamers from every selection round and numerous control sequences were all represented in triplicate. We used these identical arrays to measure the binding affinity and specificity of every candidate aptamer in parallel, in both buffer and undiluted serum.
Parallel Measurement of Affinity and Specificity. Our chip contains 120,000 in situ-synthesized features. To use this chip to measure the binding affinity of each candidate aptamer in parallel, we divided the chip into eight identical arrays and incubated each array with a different concentration of fluorescently labeled Ang2. Then, we obtained the fluorescence signal from every single aptamer feature at each different Ang2 concentration ( Fig. 2A) to construct a binding isotherm, which allowed us to derive K d values for every sequence simultaneously. Specifically, we incubated each array with 5, 10, 25, 50, 75, 100, 150, or 200 nM Alexa Fluor 647-labeled Ang2. After washing and drying, we used an array scanner to measure the fluorescence intensity (excitation = 649 nm, emission = 666 nm) from every feature. We averaged the triplicate signals from each aptamer candidate and used these data to calculate K d values. We assumed a Langmuirian binding isotherm and used the equation (28) , where Y is the net fluorescence intensity at each concentration, X is the concentration of fluorescently labeled Ang2, and B max is the net fluorescence intensity at saturation. We discarded sequences whose B max was less than double the background and thus identified 60 aptamers (SI Appendix, Table S4 ).
To illustrate how the fluorescence data from each array correlate with target binding, we present graphically rearranged fluorescence images for the six aptamers with the lowest K d s (Fig. 2B) , and the associated binding isotherms are plotted in QPASS also makes it possible to monitor the evolution of aptamer affinity such that potential "winners" can be identified in early rounds of selection before the pool has converged to a small number of sequences. For instance, after incubating the array with 50 nM fluorescently labeled Ang2, we plotted the fluorescence signal from the 235 sequences with highest copy numbers from each pool (Fig. 2D) . As expected, multiple sequences from R4 displayed high fluorescence intensities, while almost every sequence from R1−R3 showed negligible binding to Ang2. We randomly selected six sequences from R1−R3 and measured their binding to Ang2, which verified their minimal affinity (SI Appendix, Fig. S4) . Interestingly, the one notable exception was a high-affinity sequence from R3 (R3-006) that turned out to be identical with R4-002, the highest-affinity aptamer, indicating that this particular sequence had already become enriched within three rounds of low-stringency selection.
Importantly, our arrays can be used to identify aptamers that exhibit optimal binding in complex sample conditions. As proof of principle, we identified aptamers with high affinity for Ang2 in undiluted FBS. Specifically, we spiked 50 nM Alexa Fluor 647-labeled Ang2 into FBS and incubated the sample on the array for 1 h at room temperature. To ensure a high signal-to-noise ratio, we then disassembled the chip and rinsed it overnight (Methods). After background subtraction, we found eight aptamers (R4-002, -033, -039, -065, -086, -145, -201, and -227) with high affinity in serum (Fig. 3A) . Interestingly, all 8 belonged to the group of 18 aptamers that displayed the highest target affinities in buffer (Fig. 2D) . We therefore believe that our aptamer arrays can readily be used to identify aptamers that perform optimally in a variety of biological samples and assay conditions, an important consideration given that aptamer affinity and specificity can vary considerably depending on sample properties (e.g., salt concentration, pH, and temperature) (29) . Finally, we used our aptamer arrays to quantify the specificity of these aptamers for Ang2 relative to other nontarget proteins in parallel, using a two-color fluorescence scheme. As an example, we quantified the specificity of our Ang2 aptamers with BSA, the most abundant plasma protein (Fig. 3B) . We incubated the aptamer array for 1 h at room temperature with 50 nM Alexa Fluor 647-labeled Ang2 spiked into a solution of 1 μM Alexa Fluor 555-labeled BSA. After washing and drying, we imaged the array using two different excitation wavelengths: 649 nm for Alexa Fluor 647 (Ang2), and 532 nm for Alexa Fluor 555 (BSA). Although the BSA concentration was 20-fold higher, Ang2 (Fig.  3B , Left) generated a far stronger fluorescence signal than BSA for all aptamers (Fig. 3B, Right) . The relative fluorescence intensities from Ang2 and BSA are plotted in Fig. 3C . From these data, we calculated each aptamer's specificity in terms of its fluorescence ratio (i.e., Ang2 (F 647 )/BSA (F 555 )) and identified 11 aptamers (R4-002, -033, -039, -048, -086, -110, -119, -145, -159, -201, and -227) that showed the highest specificity (SI Appendix, Fig. S5 ). In this way, our aptamer arrays offer the capacity to quantify specificity in parallel and with far greater ease than conventional methods, which require collection of individual binding measurements for each aptamer.
Discussion
In this work, we describe a technology platform that accelerates discovery of high-quality aptamers by integrating microfluidic selection and NGS analysis with aptamer arrays that enable parallel characterization of affinity and specificity for large numbers of sequences. We show that the QPASS platform overcomes the limitations inherent to conventional aptamer discovery approaches. Microfluidic selection enables the use of extremely small amounts of target with controlled and reproducible imposition of selection pressures. NGS allows us to analyze vastly larger number of molecules (∼10 7 sequences) compared with conventional cloning-based methods (∼10 2 sequences), such that putative high-affinity aptamers that become enriched over the course of selection can be identified earlier and without fully converging the enriched pool. This is important, because increasing the number of selection rounds introduces and amplifies undesirable biases that may confound the discovery of targetspecific sequences (20, 30) . Most importantly, the aptamer arrays make it possible to perform quantitative measurement of both affinity and specificity for thousands of aptamer candidates simultaneously, even in complex samples such as undiluted serum. We have experimentally verified that QPASS is not only more rapid than conventional SELEX but also generates higher-quality aptamers. We performed 15 rounds of SELEX for Ang2 using nitrocellulose membranes. We obtained 94 sequences (SI Appendix, Methods), and determined that the K d of the best aptamer was 85.6 ± 22.0 nM (SI Appendix, Fig. S6 ). In contrast, QPASS generated an aptamer with ∼400% higher affinity (K d = 20.5 ± 7.33 nM) within four rounds.
Moreover, the NGS data coupled with the affinity data obtained from QPASS enable bioinformatics analyses that can identify structure and sequence elements that are critical for target binding. As an example, we analyzed a consensus group consisting of 25 sequences from the R4 pool, which included our highest-affinity aptamer (R4-002) but generally exhibited a broad range of affinities with K d s ranging from 20.5 to 152.1 nM (SI Appendix, Table S5 ). We used these binding and sequence data to explore how one-or two-nucleotide differences in the consensus motif affect the overall affinity of the aptamer. To do so, we used mfold software (31) to predict the secondary structure of R4-002 and identified a protruding stem and loop region that contains highly conserved sequence elements, implying that these regions may be critical determinants of aptamer affinity. We subsequently found specific bases in these stem and loop regions that appear to be important for binding affinity, and have graphically summarized how base changes at these positions affect overall binding affinities in SI Appendix, Fig. S7 . Notably, two thymines (T) at the 20th and 26th positions within the stem-loop region were especially critical for affinity, and their mutation to guanine (G) resulted in a sevenfold decrease of binding affinity. In this way, QPASS offers an effective means of linking sequence variations with changes in binding affinity, a capability that could be extended to highthroughput investigations of other nucleic acid structure−function relationships. Although previous work with immobilized aptamers has shown that qualitative changes in fluorescence intensity on the array are commensurate with differences in binding affinity (21, 22) , we were concerned that aptamers identified in our array may not perform equally well in free solution. We therefore validated the affinity of our aptamers using a bead-based fluorescent assay. As shown in SI Appendix, Fig. S3 , the K d values obtained for these free aptamers were in close agreement with those obtained with the array, demonstrating that the array can accurately predict binding performance in solution.
We have identified a number of opportunities for further improving the performance of QPASS in the future. For one, we found that the affinities of the selected aptamers were compromised by the limitations of the array format, which required us to eliminate primer-binding regions from the selected molecules. These DNA segments are known to play an important role in aptamer folding (32) , and we confirmed the importance of these segments in four of our most highly represented sequences from R4. Three of these four aptamers exhibited higher affinities when measured as full-length 80-nt molecules relative to just the 40-nt core segment (SI Appendix, Fig. S8 ). On the other hand, eliminating the primer-binding sequences from the aptamers on our array allowed us to identify the shorter, core sequences that contribute to binding. Nevertheless, implementation of a shorter optimized library or array synthesis platforms compatible with longer sequences should lead to discovery of higher-affinity aptamers. Although we have demonstrated the capacity of QPASS to measure aptamer specificity with BSA as a nontarget protein, future implementation of QPASS would benefit greatly from incorporation of counterselection steps with closely related proteins to maximize aptamer specificity and eliminate cross-recognition of structurally similar nontarget molecules. In the absence of such counterselection, we tested the specificity of our aptamers by measuring their affinity for angiopoietin-1 (Ang1), and observed notable binding to this closely related protein. We will therefore be implementing additional counterselections in future iterations of QPASS. In parallel, we believe that our multicolor measurement scheme could be readily extended to a wide range of nontarget molecules (including mixtures) for more extensive analysis of specificity.
A key advantage of QPASS lies in the fact that because binding measurements are performed using an in situ-synthesized array, the time and labor required for binding characterization remains relatively constant regardless of the number of molecules being analyzed. As an initial proof of concept, we synthesized relatively small 15,000-feature arrays, but custom DNA arrays with more than 1,000,000 features are already commercially available at reasonable cost to researchers, and the economic advantages of scaling will continue to accrue as feature density grows. This feature of QPASS architecture will make it inherently more cost-effective for multiplexing and characterizing aptamers for multiple targets in the future, relative to conventional serial processes. Just as large-scale integrated circuits have benefited from parallel fabrication processes in accordance with Moore's law (33), we believe parallel architectures for analysis and characterization will be a critical step for accelerating affinity reagent discovery to meet the growing demands of the postgenomic era.
Methods
Microfluidic SELEX Targeting Human Ang2. We immobilized Ang2 (R&D Systems) on the surface of micrometer-sized magnetic beads. M-270 carboxylic acid Dynabeads (Invitrogen) were activated with EDC and NHS, and target protein was immobilized after activation by following the manufacturer's procedure. Immobilized Ang2 proteins were quantified using the NanoOrange protein quantification kit (Invitrogen).
Each member of the single-stranded DNA ( . The beads were then trapped via magnetic particle concentrator (Invitrogen) for R1 and via MMS chip for R2−R4. The diluted samples were loaded into the chip at a flow rate of 100 mL/h to continuously separate protein-bound aptamers from unbound and weakly bound DNAs. Aptamer-bound beads were collected, and eluted ssDNAs were amplified by PCR using forward and phosphorylated reverse primers. The ssDNA was generated for the next round of selection by lambda exonuclease (New England Biolabs) digestion. After four rounds of selection, each selection pool was tested for binding affinity for Ang2 with a magnetic bead-based fluorescence assay.
Magnetic Bead-Based ELISA. Two-and-one-half microliters of Ang2-immobilized magnetic beads and 2.5 μL of Tris-coated magnetic beads were washed three times with phosphate buffered saline with Tween-20 (PBST) buffer (10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 , 137 mM NaCl, 2.7 mM KCl, 0.05% Tween-20, pH 7.4). Beads were blocked with 2% (wt/vol) BSA in PBST buffer on a rotator for 1 h at room temperature. After washing each bead solution three times with PBST, we split the solutions into two tubes. We incubated each aliquot with 2 μg/mL of anti-Ang2 antibody solution (R&D Systems) in 0.5% BSA with PBST buffer, along with one untreated tube containing Ang2-immobilized magnetic beads as a negative control, for 30 min on a rotator at room temperature. After three washes with PBST, we incubated the bead solutions with HRP-conjugated secondary antibody (0.8 mg/mL, Jackson ImmunoResearch Laboratories) diluted between 1:500 and 1:2,500, and incubated for 30 min on a rotator at room temperature. All bead solutions were washed three times with PBST and then transferred to new tubes. We added 100 μL of 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS, Invitrogen) to each tube and incubated for 5-60 min for color development. To stop the color reaction, we added 100 μL of ABTS stop solution and transferred all samples to an ELISA plate to obtain readings for each sample in duplicate. We used a microplate reader (Tecan) to read the OD 405 for each well.
Binding Affinity Measurements for Selected Pools with a Magnetic Bead-Based Fluorescence Assay. We tested the binding affinity of the library and each selection pool (R1−R4) for Ang2 using a fluorescence binding assay. We introduced carboxyfluorescein (FAM) labeling via PCR with FAM-labeled forward primers, and diluted the labeled library and R1-4 DNA pools to various different concentrations ranging from 0 to 100 nM. These pools were heated to 95°C for 10 min, and then immediately cooled down in an ice bath. Two × 10 6 Ang2-coated magnetic beads were washed three times in Ang2 binding buffer and incubated with the various DNA pools at room temperature for 1 h. To remove unbound DNA, the beads were washed three times with Ang2 wash buffer. Bound DNAs were then eluted from the beads by heating at 95°C for 10 min. Released DNAs were quantified by fluorescence measurement using a microplate reader (excitation = 490 nm, emission = 520 nm). Dissociation constants (K d ) were calculated by nonlinear fitting analysis.
Aptamer Array Design and Synthesis. We designed and ordered custom 8 × 15,000 DNA microarrays through the custom microarray program from Agilent. Each slide consisted of eight identical arrays of 15,000 individual features. The array design was based on the aptamer candidates identified from sequencing. The 235 aptamer candidates with the most copies from each round were incorporated into the array design, along with 65 negative control DNA molecules including primer repeats and aptamers specific for other targets (human α thrombin and PDGF-BB) (SI Appendix, Table S2 ). Each sequence was synthesized in triplicate, with each molecule anchored by either a 3′ poly-T20 linker or one of three other alternative linkers (SI Appendix, Table S3 ).
Fluorescence Labeling of Proteins. Ang2 was labeled with Alexa Fluor 647 (Invitrogen) dye according to the manufacturer's protocol. Briefly, 1 mg/mL of Ang2 (in 100 mM NaHCO 3 , pH 8.3) was incubated with 3 μL of Alexa Fluor 647 succinimidyl ester (7.94 nmol/μL) for 1 h at room temperature. To separate labeled protein from unreacted dye, we used a spin column and the supplied purification resin with Ang2 binding buffer. The eluted conjugates were analyzed using a NanoDrop Technologies ND-1000 spectrophotometer. We obtained a ∼95% yield of conjugate, with an 8.75 degree of labeling. The labeled protein was stored at 4°C, protected from light. BSA (BSA) was labeled with Alexa Fluor 555 dye according to same protocol. We obtained a ∼95% yield of conjugate, with a degree of labeling of 9.35.
Binding and Specificity Experiments on Aptamer Array. Slides were assembled with eight-well gaskets in an Agilent hybridization chamber for blocking and sample incubation. Each gasket was filled with 40 μL of blocking or sample solution. Before binding Alexa Fluor 647-labeled Ang2 to the array, we blocked the array surface for 1 h at room temperature with blocking buffer (10 mg/mL casein, 0.1% Tween-20, 10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 , 2.7 mM KCl, 137 mM NaCl, 1 mM MgCl 2 , pH 7.4). Slides were disassembled in nanopure H 2 O and then dried by centrifugation (130 × g for 2 min using a swing bucket rotor). Different concentrations of labeled Ang2 (5, 10, 25, 50, 75, 100, 150, and 200 nM) were diluted in blocking buffer and incubated on the arrays for 1 h at room temperature. For specificity tests, 1 μM Alexa Fluor 555-labeled BSA was mixed with 50 nM Alexa Fluor 647-labeled Ang2 and then added to the array. Slides were disassembled in washing buffer (0.1% Tween-20, 10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 , 2.7 mM KCl, 137 mM NaCl, 1 mM MgCl 2 , pH 7.4) and rinsed three times in washing buffer with decreasing amounts of Tween-20 (0.1%, 0.01%, and 0.001% of . After a final wash with nanopure H 2 O, slides were dried by centrifugation (1,500 rpm for 2 min using a swing bucket rotor).
For binding experiments in undiluted serum, 50 nM Alexa Fluor 647-labeled Ang2 was spiked into 100% FBS (Invitrogen) and then incubated on the arrays for 1 h at room temperature. Slides were disassembled in washing buffer with 0.1% Tween-20 and rinsed overnight. After a final wash with nanopure H 2 O, slides were dried by centrifugation (1,500 rpm for 2 min using a swing bucket rotor).
Slides were scanned using a Perkin-Elmer Proscan array HT reader at 5-μm resolution. Data were extracted from images using ImaGene 7.5 software (BioDiscovery), and dissociation constants were calculated by computational nonlinear least squares fitting in a Microsoft Excel worksheet (28) .
